Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + Pyrotinib in HER2+ Breast Cancer
NCT07132242Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in breast cancer (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Objective Response Rate up to 36 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07132242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132242.